Unicycive Therapeutics, Inc.
UNCY Nasdaq
SEC CIK 1766140
Follow Unicycive Therapeutics
Weekly email: filings, results
Net income
−$7M
−16.4% vs same quarter last year
EPS, diluted
−$0.25
+24.2% vs same quarter last year
Operating cash flow
−$7.2M
−21.6% vs same quarter last year
Operating income
−$8.8M
−20.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$26.6M |
| FY24 | −$36.7M |
| FY23 | −$30.5M |
| FY22 | −$18.1M |
| FY21 | −$10M |
| FY20 | −$2.3M |
| FY19 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$31.3M |
| FY24 | −$28.6M |
| FY23 | −$18.3M |
| FY22 | −$15.7M |
| FY21 | −$5.8M |
| FY20 | - |
| FY19 | - |